Xtl Biopharmaceuticals Ltd Stock Alpha and Beta Analysis

XTLB Stock  USD 1.88  0.05  2.73%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as XTL Biopharmaceuticals Ltd. It also helps investors analyze the systematic and unsystematic risks associated with investing in XTL Biopharmaceutica over a specified time horizon. Remember, high XTL Biopharmaceutica's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to XTL Biopharmaceutica's market risk premium analysis include:
Beta
0.79
Alpha
(0.46)
Risk
6.79
Sharpe Ratio
(0.04)
Expected Return
(0.30)
Please note that although XTL Biopharmaceutica alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, XTL Biopharmaceutica did 0.46  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of XTL Biopharmaceuticals Ltd stock's relative risk over its benchmark. XTL Biopharmaceuticals has a beta of 0.79  . As returns on the market increase, XTL Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding XTL Biopharmaceutica is expected to be smaller as well. At present, XTL Biopharmaceutica's Price Book Value Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 2.41, whereas Book Value Per Share is forecasted to decline to 0.

Enterprise Value

3.88 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out XTL Biopharmaceutica Backtesting, XTL Biopharmaceutica Valuation, XTL Biopharmaceutica Correlation, XTL Biopharmaceutica Hype Analysis, XTL Biopharmaceutica Volatility, XTL Biopharmaceutica History and analyze XTL Biopharmaceutica Performance.

XTL Biopharmaceutica Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. XTL Biopharmaceutica market risk premium is the additional return an investor will receive from holding XTL Biopharmaceutica long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in XTL Biopharmaceutica. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate XTL Biopharmaceutica's performance over market.
α-0.46   β0.79

XTL Biopharmaceutica expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of XTL Biopharmaceutica's Buy-and-hold return. Our buy-and-hold chart shows how XTL Biopharmaceutica performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

XTL Biopharmaceutica Market Price Analysis

Market price analysis indicators help investors to evaluate how XTL Biopharmaceutica stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading XTL Biopharmaceutica shares will generate the highest return on investment. By understating and applying XTL Biopharmaceutica stock market price indicators, traders can identify XTL Biopharmaceutica position entry and exit signals to maximize returns.

XTL Biopharmaceutica Return and Market Media

The median price of XTL Biopharmaceutica for the period between Mon, Aug 26, 2024 and Sun, Nov 24, 2024 is 2.3 with a coefficient of variation of 16.94. The daily time series for the period is distributed with a sample standard deviation of 0.38, arithmetic mean of 2.22, and mean deviation of 0.33. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Biopharmaceuticals Manufacturing Consumables Testing Business Research Report 2024-2030
10/18/2024
2
Bioreactors Market Set to Witness Significant Growth by 2030, Driven by Rising Demand in Biopharmaceuticals
10/22/2024
3
Day One Biopharmaceuticals earnings beat by 0.99, revenue topped estimates
10/31/2024
4
Wall Street Analysts See a 136.83 percent Upside in Day One Biopharmaceuticals Can the Stock Really Move This High
11/06/2024
5
Provectus Biopharmaceuticals GAAP EPS of 0.00, revenue of 0.11M
11/14/2024
6
Day One Biopharmaceuticals, Inc. Sees Large Growth in Short Interest
11/18/2024
7
XTL Biopharmaceuticals adjusts ADS and warrants
11/20/2024
8
Continuous Manufacturing Strategic Industry Research Report 2024-2030 Demand for Faster Production Times in Biopharmaceuticals Drives Growth for Biologics and C...
11/21/2024

About XTL Biopharmaceutica Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including XTL or other stocks. Alpha measures the amount that position in XTL Biopharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Days Sales Outstanding22.3321.21
PTB Ratio2.32.41

XTL Biopharmaceutica Upcoming Company Events

As portrayed in its financial statements, the presentation of XTL Biopharmaceutica's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of XTL Biopharmaceutica's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of XTL Biopharmaceutica. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.
27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Build Portfolio with XTL Biopharmaceutica

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
XTL Biopharmaceutica technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of XTL Biopharmaceutica technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of XTL Biopharmaceutica trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...